About Market Research Forecast

MR Forecast provides premium market intelligence on deep technologies that can cause a high level of disruption in the market within the next few years. When it comes to doing market viability analyses for technologies at very early phases of development, MR Forecast is second to none. What sets us apart is our set of market estimates based on secondary research data, which in turn gets validated through primary research by key companies in the target market and other stakeholders. It only covers technologies pertaining to Healthcare, IT, big data analysis, block chain technology, Artificial Intelligence (AI), Machine Learning (ML), Internet of Things (IoT), Energy & Power, Automobile, Agriculture, Electronics, Chemical & Materials, Machinery & Equipment's, Consumer Goods, and many others at MR Forecast. Market: The market section introduces the industry to readers, including an overview, business dynamics, competitive benchmarking, and firms' profiles. This enables readers to make decisions on market entry, expansion, and exit in certain nations, regions, or worldwide. Application: We give painstaking attention to the study of every product and technology, along with its use case and user categories, under our research solutions. From here on, the process delivers accurate market estimates and forecasts apart from the best and most meaningful insights.

Products generically come under this phrase and may imply any number of goods, components, materials, technology, or any combination thereof. Any business that wants to push an innovative agenda needs data on product definitions, pricing analysis, benchmarking and roadmaps on technology, demand analysis, and patents. Our research papers contain all that and much more in a depth that makes them incredibly actionable. Products broadly encompass a wide range of goods, components, materials, technologies, or any combination thereof. For businesses aiming to advance an innovative agenda, access to comprehensive data on product definitions, pricing analysis, benchmarking, technological roadmaps, demand analysis, and patents is essential. Our research papers provide in-depth insights into these areas and more, equipping organizations with actionable information that can drive strategic decision-making and enhance competitive positioning in the market.

U.S. Infectious Disease Point-of-care (POC) Diagnostics Market

U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Strategic Roadmap: Analysis and Forecasts 2025-2033

U.S. Infectious Disease Point-of-care (POC) Diagnostics Market by Technique (Lateral Flow Immunoassay, Agglutination Test, Flow-through Test, Molecular Diagnostics, Others), by Disease (Human Immunodeficiency Virus (HIV), by End-user (Hospitals, Physician’s Offices, Urgent Care & Retail Clinics, Others), by U.S. Forecast 2026-2034

Oct 16 2025

Base Year: 2025

70 Pages

U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Strategic Roadmap: Analysis and Forecasts 2025-2033

Key Insights

The size of the U.S. Infectious Disease Point-of-care (POC) Diagnostics Market was valued at USD 227.0 USD Million in 2023 and is projected to reach USD 341.32 USD Million by 2032, with an expected CAGR of 6.0% during the forecast period. Infectious disease point-of-care (POC) diagnostics in the U.S. refer to diagnostic tests and technologies designed to detect infections at or near the site of patient care, typically outside of traditional laboratory settings. These tests enable quick, on-site results, facilitating faster diagnosis and treatment, which is critical for controlling the spread of infectious diseases and improving patient outcomes. POC diagnostics are particularly important in urgent care settings, emergency departments, and for patients with limited access to healthcare facilities.

U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Trends

Key market trends driving the growth of the U.S. Infectious Disease POC Diagnostics Market include:

U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Market Size and Forecast (2024-2030) — U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Company Market Share

Driving Forces: What's Propelling the U.S. Infectious Disease Point-of-care (POC) Diagnostics Market

The U.S. Infectious Disease POC Diagnostics Market is experiencing robust expansion driven by a confluence of critical factors:

Escalating Infectious Disease Burden: The persistent and, in some cases, increasing prevalence of both endemic and emerging infectious diseases within the U.S. necessitates rapid, accessible diagnostic solutions. This demand is fueled by the need for timely intervention, effective containment strategies, and improved patient management to mitigate the impact of outbreaks and individual infections.
Transformative Technological Innovations: Continuous advancements in POC diagnostic technologies are revolutionizing the field. Innovations in areas such as microfluidics, biosensors, molecular diagnostics, and user-friendly interfaces are leading to POC devices that offer enhanced sensitivity, improved specificity, faster turnaround times, and broader multiplexing capabilities. These improvements expand the range of detectable pathogens and biomarkers, making POC testing more versatile and reliable.
Proactive Government and Regulatory Support: Government initiatives, including funding for research and development, favorable regulatory pathways for emergency use authorizations (EUAs) and streamlined approvals, and public health campaigns promoting early detection, are significantly bolstering the market. Organizations like the CDC and FDA play a crucial role in setting standards, providing guidelines, and encouraging the adoption of effective POC diagnostic tools.
Unmet Demand for Rapid and Decentralized Testing: The inherent need for immediate diagnostic results, particularly in critical care settings, during public health emergencies, and in remote or underserved areas, is a primary market driver. POC diagnostics empower healthcare professionals to make informed clinical decisions at the patient's bedside, reducing delays in treatment initiation and improving overall patient care efficiency.
Shift Towards Value-Based Healthcare: The broader healthcare landscape's focus on value-based care, emphasizing cost-effectiveness and improved patient outcomes, favors the adoption of POC diagnostics. By enabling earlier diagnosis and treatment, POC tests can potentially reduce downstream healthcare costs associated with complications and prolonged hospital stays.

Challenges and Restraints in U.S. Infectious Disease Point-of-care (POC) Diagnostics Market

While the U.S. Infectious Disease POC Diagnostics Market demonstrates substantial growth potential, several hurdles and limitations need to be addressed for its full realization:

Cost-Effectiveness and Reimbursement Landscape: The initial investment in some advanced POC devices and consumables can be higher compared to conventional laboratory testing. Furthermore, inconsistent or inadequate reimbursement policies from payers can hinder adoption, particularly for smaller clinics and healthcare facilities, impacting the accessibility and affordability of these crucial diagnostic tools.
Navigating Complex Regulatory Pathways: Obtaining regulatory clearance from bodies like the FDA for new POC diagnostic tests and devices can be a lengthy and resource-intensive process. While expedited pathways exist, the stringent requirements for analytical and clinical validation can present significant challenges for manufacturers, potentially delaying market entry and innovation.
Ensuring Operator Proficiency and Standardization: The performance and accuracy of many POC tests are highly dependent on the skill, training, and adherence to protocols by the healthcare professional administering the test. Variability in operator expertise can lead to discrepancies in results, underscoring the need for comprehensive training programs and robust quality control measures to ensure reliable outcomes.
Scope of Disease Coverage and Diagnostic Certainty: While the range of infectious diseases detectable by POC diagnostics is constantly expanding, there remain specific pathogens or disease stages for which highly sensitive and specific POC tests are not yet available. This can necessitate confirmatory testing in centralized laboratories, limiting the complete decentralization of diagnostic capabilities for certain conditions.
Data Integration and Interoperability: Seamless integration of POC device data into existing Electronic Health Record (EHR) systems and hospital information systems can be a technical challenge. Lack of interoperability can impede real-time data sharing, disease surveillance, and efficient clinical decision-making.

Key Region or Country & Segment to Dominate the Market

Dominant Region: The United States unequivocally holds the position as the leading market for Infectious Disease POC Diagnostics. This market supremacy is a direct consequence of its sophisticated healthcare infrastructure, substantial investment in medical research and development, high prevalence of various infectious diseases, and a robust ecosystem of technology developers and healthcare providers. The established reimbursement frameworks and a strong emphasis on rapid diagnostics in clinical settings further solidify its dominance.

Dominant Segment: Within the U.S. market, Lateral Flow Immunoassay (LFI)-based diagnostics continue to be the most dominant segment. Their enduring popularity stems from their inherent simplicity of use, portability, rapid result generation (often within minutes), and relatively low cost of manufacturing. These attributes make LFI tests ideal for a wide array of settings, from emergency rooms and physician offices to community health centers and point-of-care testing outside traditional healthcare facilities.

Growth Catalysts in U.S. Infectious Disease Point-of-care (POC) Diagnostics Industry

The U.S. Infectious Disease POC Diagnostics Industry is primed for sustained and accelerated growth, propelled by several potent catalysts:

Expanding Applications in Public Health and Clinical Practice: POC diagnostics are increasingly being integrated into broader public health strategies, including robust outbreak preparedness and response, routine infectious disease screening in diverse settings (e.g., schools, workplaces), and chronic disease management where co-infections are a concern. Their utility in decentralized testing for conditions like influenza, strep throat, UTIs, and sexually transmitted infections (STIs) continues to grow.
Synergistic Integration of AI and IoT Technologies: The convergence of Artificial Intelligence (AI) and the Internet of Things (IoT) is a significant growth enabler. AI algorithms can enhance the analytical capabilities of POC devices, enabling more accurate interpretation of results and predictive diagnostics. IoT connectivity allows for remote monitoring, real-time data transmission to healthcare providers and public health agencies, device calibration, and efficient inventory management, creating smarter and more interconnected diagnostic ecosystems.
Heightened Emphasis on Point-of-Need and Patient-Centric Care: The paradigm shift towards patient-centric healthcare models strongly favors the deployment of POC diagnostics. By bringing testing closer to the patient, these solutions reduce patient anxiety, minimize the need for travel and follow-up appointments, and empower individuals with faster access to information about their health, thereby improving adherence to treatment plans.
Increased Awareness, Education, and Training Initiatives: Growing recognition of the benefits of POC diagnostics among healthcare professionals, policymakers, and the general public is a key growth driver. Ongoing educational campaigns, professional training programs, and demonstration of successful POC implementations are fostering greater trust and encouraging wider adoption across the healthcare continuum.
Development of Multiplexed and Next-Generation POC Platforms: The ongoing development of POC platforms capable of detecting multiple pathogens or biomarkers simultaneously (multiplexing) offers significant advantages in terms of efficiency and comprehensive diagnostic information. Furthermore, advancements in molecular POC technologies (e.g., isothermal amplification) are bringing laboratory-grade accuracy to the point of care, expanding the diagnostic capabilities for a wider range of infectious agents.

Leading Players in the U.S. Infectious Disease Point-of-care (POC) Diagnostics Market

The U.S. Infectious Disease POC Diagnostics Market is highly competitive, with several leading players operating in the market, including:

Significant Developments in U.S. Infectious Disease Point-of-care (POC) Diagnostics Sector

The U.S. Infectious Disease POC Diagnostics Sector has witnessed several significant developments in recent years:

May 2023: bioMérieux announced the U.S. FDA CLIA waiver for its BIOFIRE SPOTFIRE Respiratory (R) Panel Mini, a point-of-care system that provides rapid and accurate detection of respiratory pathogens, including Influenza A, SARS-CoV-2, and RSV.
March 2023: bioMérieux made a strategic investment in Proxim Diagnostics Corp., a U.S.-based point-of-care diagnostics company, to support the development and commercialization of the Proxim Profile System for infectious disease, cardiology, and sepsis diagnostics.
March 2021: Cardinal Health collaborated with eMed, LLC, a digital point-of-care solution provider, to distribute At-Home COVID-19 rapid tests to pharmacies across the U.S., expanding access to convenient and reliable testing options.

Comprehensive Coverage U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Report

Our comprehensive U.S. Infectious Disease POC Diagnostics Market Report provides an in-depth analysis of the market, covering various aspects such as:

Market Dynamics: Presents key market drivers, restraints, trends, and challenges shaping the market landscape.
Market Size and Forecast: Provides historical, current, and projected market size, along with detailed segmentation.
Market Segmentation: Classifies the market based on technique, disease, and end-user, offering insights into the performance of each segment.
Competitive Landscape: Profiles the leading companies, their market share, product portfolios, financial performance, and recent developments.
Growth Strategies: Explores the key growth strategies adopted by players, including product innovation, strategic partnerships, and market expansion.
Future Outlook: Discusses the potential opportunities and challenges for the market, along with projections for the future.

DROCT

Global DROCT (Diagnostic Related Group Outpatient Procedures): Provides data on outpatient procedures and their associated costs.
Medicare DROCT: Focuses on the DROCT system used by Medicare, providing detailed information on payment rates and reimbursement policies.

Pricing Analysis

Pricing Trends: Analyzes the historical and current pricing trends for Infectious Disease POC Diagnostics in the U.S. market.
Pricing Strategies: Examines the pricing strategies employed by leading market players.
Regional Price Variations: Compares pricing across different regions and states within the U.S.

Import And Export Analysis

Import Trends: Examines the historical and current import trends for Infectious Disease POC Diagnostics in the U.S.
Export Trends: Analyzes the historical and current export trends for Infectious Disease POC Diagnostics from the U.S.
Trade Balance: Evaluates the trade balance between imports and exports, providing insights into the U.S.'s position in the global market.

Patent/Trademark Analysis

Patent Landscape: Provides a

U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Segmentation

1. Technique
- 1.1. Lateral Flow Immunoassay
- 1.2. Agglutination Test
- 1.3. Flow-through Test
- 1.4. Molecular Diagnostics
- 1.5. Others
2. Disease
- 2.1. Human Immunodeficiency Virus (HIV
3. End-user
- 3.1. Hospitals
- 3.2. Physician’s Offices
- 3.3. Urgent Care & Retail Clinics
- 3.4. Others

U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Segmentation By Geography

1. U.S.

U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Market Share by Region - Global Geographic Distribution — U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Regional Market Share

Geographic Coverage of U.S. Infectious Disease Point-of-care (POC) Diagnostics Market

Higher Coverage

Lower Coverage

No Coverage

U.S. Infectious Disease Point-of-care (POC) Diagnostics Market REPORT HIGHLIGHTS

Aspects	Details
Study Period	2020-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2020-2025
Growth Rate	CAGR of 6.0% from 2020-2034
Segmentation	By Technique Lateral Flow Immunoassay Agglutination Test Flow-through Test Molecular Diagnostics Others By Disease Human Immunodeficiency Virus (HIV By End-user Hospitals Physician’s Offices Urgent Care & Retail Clinics Others By Geography U.S.

1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
- 2.1. Introduction
3. Market Dynamics
- 3.1. Introduction
- - 3.2. Market Drivers
  - - 3.2.1. Increasing Number of Product Approval and Launches to Drive Market Growth
- - 3.3. Market Restrains
  - - 3.3.1. Increasing Number of Product Approval and Launches to Drive Market Growth
- - 3.4. Market Trends
  - - 3.4.1. Increasing Number of Product Approval and Launches to Drive Market Growth
4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
5. U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Technique
  - 5.1.1. Lateral Flow Immunoassay
  - 5.1.2. Agglutination Test
  - 5.1.3. Flow-through Test
  - 5.1.4. Molecular Diagnostics
  - 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast - by Disease
  - 5.2.1. Human Immunodeficiency Virus (HIV
- 5.3. Market Analysis, Insights and Forecast - by End-user
  - 5.3.1. Hospitals
  - 5.3.2. Physician’s Offices
  - 5.3.3. Urgent Care & Retail Clinics
  - 5.3.4. Others
- 5.4. Market Analysis, Insights and Forecast - by Region
  - 5.4.1. U.S.
6. Competitive Analysis
- 6.1. Market Share Analysis 2025
- - 6.2. Company Profiles
  - - 6.2.1 F. Hoffmann-La Roche Ltd (Switzerland)
      6.2.1.1. Overview
      6.2.1.2. Products
      6.2.1.3. SWOT Analysis
      6.2.1.4. Recent Developments
      6.2.1.5. Financials (Based on Availability)
    - 6.2.2 Thermo Fisher Scientific Inc. (U.S.)
      6.2.2.1. Overview
      6.2.2.2. Products
      6.2.2.3. SWOT Analysis
      6.2.2.4. Recent Developments
      6.2.2.5. Financials (Based on Availability)
    - 6.2.3 Abbott Laboratories (U.S.)
      6.2.3.1. Overview
      6.2.3.2. Products
      6.2.3.3. SWOT Analysis
      6.2.3.4. Recent Developments
      6.2.3.5. Financials (Based on Availability)
    - 6.2.4 Quest Diagnostics Incorporated (U.S.)
      6.2.4.1. Overview
      6.2.4.2. Products
      6.2.4.3. SWOT Analysis
      6.2.4.4. Recent Developments
      6.2.4.5. Financials (Based on Availability)
    - 6.2.5 BD (U.S.)
      6.2.5.1. Overview
      6.2.5.2. Products
      6.2.5.3. SWOT Analysis
      6.2.5.4. Recent Developments
      6.2.5.5. Financials (Based on Availability)
    - 6.2.6 bioMérieux SA (France)
      6.2.6.1. Overview
      6.2.6.2. Products
      6.2.6.3. SWOT Analysis
      6.2.6.4. Recent Developments
      6.2.6.5. Financials (Based on Availability)
    - 6.2.7 Cardinal Health Inc. (U.S.)
      6.2.7.1. Overview
      6.2.7.2. Products
      6.2.7.3. SWOT Analysis
      6.2.7.4. Recent Developments
      6.2.7.5. Financials (Based on Availability)
    - 6.2.8 Cepheid (U.S.)
      6.2.8.1. Overview
      6.2.8.2. Products
      6.2.8.3. SWOT Analysis
      6.2.8.4. Recent Developments
      6.2.8.5. Financials (Based on Availability)
    - 6.2.9 Trinity Biotech (Ireland)
      6.2.9.1. Overview
      6.2.9.2. Products
      6.2.9.3. SWOT Analysis
      6.2.9.4. Recent Developments
      6.2.9.5. Financials (Based on Availability)
    - 6.2.10 Quidel Corporation (U.S.)
      6.2.10.1. Overview
      6.2.10.2. Products
      6.2.10.3. SWOT Analysis
      6.2.10.4. Recent Developments
      6.2.10.5. Financials (Based on Availability)
    - 6.2.11 Bio-Rad Laboratories Inc. (U.S.)
      6.2.11.1. Overview
      6.2.11.2. Products
      6.2.11.3. SWOT Analysis
      6.2.11.4. Recent Developments
      6.2.11.5. Financials (Based on Availability)

List of Figures

Figure 1: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Revenue Breakdown (USD Million, %) by Product 2025 & 2033
Figure 2: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Share (%) by Company 2025

List of Tables

Table 1: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Revenue USD Million Forecast, by Technique 2020 & 2033
Table 2: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Revenue USD Million Forecast, by Disease 2020 & 2033
Table 3: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Revenue USD Million Forecast, by End-user 2020 & 2033
Table 4: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Revenue USD Million Forecast, by Region 2020 & 2033
Table 5: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Revenue USD Million Forecast, by Technique 2020 & 2033
Table 6: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Revenue USD Million Forecast, by Disease 2020 & 2033
Table 7: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Revenue USD Million Forecast, by End-user 2020 & 2033
Table 8: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Revenue USD Million Forecast, by Country 2020 & 2033

Methodology

Step 1 - Identification of Relevant Samples Size from Population Database

Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.

Note*: In applicable scenarios

Step 3 - Data Sources

Primary Research

Web Analytics
Survey Reports
Research Institute
Latest Research Reports
Opinion Leaders

Secondary Research

Annual Reports
White Paper
Latest Press Release
Industry Association
Paid Database
Investor Presentations

Step 4 - Data Triangulation

Involves using different sources of information in order to increase the validity of a study

These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.

Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.

During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence

Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.

Frequently Asked Questions

1. What is the projected Compound Annual Growth Rate (CAGR) of the U.S. Infectious Disease Point-of-care (POC) Diagnostics Market?

The projected CAGR is approximately 6.0%.

2. Which companies are prominent players in the U.S. Infectious Disease Point-of-care (POC) Diagnostics Market?

Key companies in the market include F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Quest Diagnostics Incorporated (U.S.), BD (U.S.), bioMérieux SA (France), Cardinal Health, Inc. (U.S.), Cepheid (U.S.), Trinity Biotech (Ireland), Quidel Corporation (U.S.), Bio-Rad Laboratories Inc. (U.S.).

3. What are the main segments of the U.S. Infectious Disease Point-of-care (POC) Diagnostics Market?

The market segments include Technique, Disease, End-user.

4. Can you provide details about the market size?

The market size is estimated to be USD 227.0 USD Million as of 2022.

5. What are some drivers contributing to market growth?

Increasing Number of Product Approval and Launches to Drive Market Growth.

6. What are the notable trends driving market growth?

Increasing Number of Product Approval and Launches to Drive Market Growth.

7. Are there any restraints impacting market growth?

Increasing Number of Product Approval and Launches to Drive Market Growth.

8. Can you provide examples of recent developments in the market?

May 2023: bioMérieux announced that the company received the U.S. FDA CLIA waiver for its BIOFIRE SPOTFIRE Respiratory (R) Panel Mini. The BIOFIRE SPOTFIRE is a point-of-care system that provides results within 20 minutes and can detect Influenza A, SARS-CoV-2, Influenza B, Rhinovirus and Respiratory Syncytial Virus (RSV).

9. What pricing options are available for accessing the report?

Pricing options include single-user, multi-user, and enterprise licenses priced at USD 2850, USD 3850, and USD 4850 respectively.

10. Is the market size provided in terms of value or volume?

The market size is provided in terms of value, measured in USD Million.

11. Are there any specific market keywords associated with the report?

Yes, the market keyword associated with the report is "U.S. Infectious Disease Point-of-care (POC) Diagnostics Market," which aids in identifying and referencing the specific market segment covered.

12. How do I determine which pricing option suits my needs best?

The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.

13. Are there any additional resources or data provided in the U.S. Infectious Disease Point-of-care (POC) Diagnostics Market report?

While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.

14. How can I stay updated on further developments or reports in the U.S. Infectious Disease Point-of-care (POC) Diagnostics Market?

To stay informed about further developments, trends, and reports in the U.S. Infectious Disease Point-of-care (POC) Diagnostics Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.

Get Free Sample

Pre Order Enquiry Request discount

Pricing

Related Reports

Infectious Disease Point-of-care (POC) Diagnostics Market Report Probes the USD Billion Size, Share, Growth Report and Future Analysis by 2033

U.S. Point of Care Diagnostics Market Soars to USD Billion , witnessing a CAGR of 7.9 during the forecast period 2025-2033

Point-of-care Infectious Disease Diagnostics Is Set To Reach XXX million By 2033, Growing At A CAGR Of XX

Infectious Disease POC Diagnostic Report Probes the 2634.7 million Size, Share, Growth Report and Future Analysis by 2033

Point-of-care Testing (POCT) for Infectious Diseases Insightful Analysis: Trends, Competitor Dynamics, and Opportunities 2025-2033

Tailored for you

In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions
Customized Evaluation of Competitive Landscape to Meet Your Needs
Tailored Customization to Address Other Specific Requirements

Ask for customization

The response was good, and I got what I was looking for as far as the report. Thank you for that.

Erik Perison

US TPS Business Development Manager at Thermon

As requested- presale engagement was good, your perseverance, support and prompt responses were noted. Your follow up with vm’s were much appreciated. Happy with the final report and post sales by your team.

Shankar Godavarti

Global Product, Quality & Strategy Executive- Principal Innovator at Donaldson

I have received the report already. Thanks you for your help.it has been a pleasure working with you. Thank you againg for a good quality report